Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin Bremer

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Molecular Cancer|April 19, 2014
Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell deathKim L Brunekreeft, Corinna Strohm, Marloes J Gooden, et al.
Cancer Research|January 18, 2008
Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonistsEdwin Bremer, Bram ten Cate, Douwe F Samplonius, et al.
Plos One|June 7, 2013
Galectin-9 activates and expands human T-helper 1 cellsMarloes J M Gooden, Valerie R Wiersma, Douwe F Samplonius, et al.
International Journal of Pharmaceutics: X|May 25, 2026
A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug productsRobin Dennebos, Macarena González-Corrales, Maria Lysandrou, et al.
Cancer Immunology Research|August 15, 2019
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCLRenée Bouwstra, Yuan He, Janneke de Boer, et al.
Experimental Hematology & Oncology|March 30, 2024
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responsesYusheng Lin, Ghizlane Choukrani, Lena Dubbel, et al.
Mabs|March 12, 2015
C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicityValerie R Wiersma, Marco de Bruyn, Ce Shi, et al.
Cancer Immunology, Immunotherapy : CII|August 1, 2007
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion proteinJulia Stieglmaier, Edwin Bremer, Christian Kellner, et al.
Oncoimmunology|January 9, 2018
CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumabPeter E van Bommel, Yuan He, Ilona Schepel, et al.
Autophagy|June 19, 2015
The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic fluxValerie R Wiersma, Marco de Bruyn, Yunwei Wei, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Molecular Cancer|April 19, 2014
Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell deathKim L Brunekreeft, Corinna Strohm, Marloes J Gooden, et al.
Cancer Research|January 18, 2008
Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonistsEdwin Bremer, Bram ten Cate, Douwe F Samplonius, et al.
Plos One|June 7, 2013
Galectin-9 activates and expands human T-helper 1 cellsMarloes J M Gooden, Valerie R Wiersma, Douwe F Samplonius, et al.
International Journal of Pharmaceutics: X|May 25, 2026
A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug productsRobin Dennebos, Macarena González-Corrales, Maria Lysandrou, et al.
Cancer Immunology Research|August 15, 2019
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCLRenée Bouwstra, Yuan He, Janneke de Boer, et al.
Experimental Hematology & Oncology|March 30, 2024
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responsesYusheng Lin, Ghizlane Choukrani, Lena Dubbel, et al.
Mabs|March 12, 2015
C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicityValerie R Wiersma, Marco de Bruyn, Ce Shi, et al.
Cancer Immunology, Immunotherapy : CII|August 1, 2007
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion proteinJulia Stieglmaier, Edwin Bremer, Christian Kellner, et al.
Oncoimmunology|January 9, 2018
CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumabPeter E van Bommel, Yuan He, Ilona Schepel, et al.
Autophagy|June 19, 2015
The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic fluxValerie R Wiersma, Marco de Bruyn, Yunwei Wei, et al.
Pageof 10